BTX-A51
Acute Myeloid Leukemia (AML)
Key Facts
About Edgewood Oncology
Edgewood Oncology is a private, clinical-stage biotech based in San Diego, advancing its lead asset BTX-A51, a first-in-class, multi-specific inhibitor of CK1α, CDK7, and CDK9. The compound has shown promising early clinical activity and a favorable safety profile in Phase 1 studies in AML and solid tumors, and is now being explored in investigator-sponsored studies for liposarcoma. The company's strategy focuses on genetically-defined cancers, leveraging a novel mechanism that indirectly inhibits key survival proteins like MDM2 and MCL-1 to activate p53 and apoptosis.
View full company profileAbout Edgewood Oncology
Edgewood Oncology is a private, clinical-stage biotech based in San Diego, advancing its lead asset BTX-A51, a first-in-class, multi-specific inhibitor of CK1α, CDK7, and CDK9. The compound has shown promising early clinical activity and a favorable safety profile in Phase 1 studies in AML and solid tumors, and is now being explored in investigator-sponsored studies for liposarcoma. The company's strategy focuses on genetically-defined cancers, leveraging a novel mechanism that indirectly inhibits key survival proteins like MDM2 and MCL-1 to activate p53 and apoptosis.
View full company profileAbout Edgewood Oncology
Edgewood Oncology is a private, clinical-stage biotech based in San Diego, advancing its lead asset BTX-A51, a first-in-class, multi-specific inhibitor of CK1α, CDK7, and CDK9. The compound has shown promising early clinical activity and a favorable safety profile in Phase 1 studies in AML and solid tumors, and is now being explored in investigator-sponsored studies for liposarcoma. The company's strategy focuses on genetically-defined cancers, leveraging a novel mechanism that indirectly inhibits key survival proteins like MDM2 and MCL-1 to activate p53 and apoptosis.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| NC525 | NextCure | Preclinical |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |